Abstract:Targeting tumor metabolism through dietary interventions is an area of growing interest, and may help to improve the significant mortality of aggressive cancers, including non-small cell lung cancer (NSCLC). Here we show that the restriction of methionine in the aggressive KRAS/Lkb1-mutant NSCLC autochthonous mouse model drives decreased tumor progression and increased carboplatin treatment efficacy. Importantly, methionine restriction during early stages of tumorigenesis prevents the lineage switching known to occur in the model, and alters the tumor immune microenvironment (TIME) to have fewer tumor-infiltrating neutrophils. Mechanistically, mutations in LKB1 are linked to anti-oxidant production through changes to cystathionine-β-synthase (CBS) expression. Human cell lines with rescued LKB1 show increased CBS levels and resistance to carboplatin, which can be partially rescued by methionine restriction. Furthermore, LKB1 rescued cells, but not mutant cells, show less G2-M arrest and apoptosis in high methionine conditions. Knock-down of CBS sensitized both LKB1 mutant and non-mutated lines to carboplatin, again rescuing the carboplatin resistance of the LKB1 rescued lines. Given that immunotherapy is commonly combined with chemotherapy for NSCLC, we next wanted to understand if T cells are impaired by MR. Therefore, we examined the ability of T cells from MR and control tumor bearing mice to proliferate in culture and found that T cells from MR treated mice had no defects in proliferation, even though we continued the MR conditions ex vivo. We also identified that CBS is most highly correlated with smoking, adenocarcinomas with alveolar and bronchiolar features, and adenosquamous cell carcinomas, implicating its roles in oxidative stress response and lineage fate in human tumors. Taken together, we have shown the importance of MR as a dietary intervention to slow tumor growth and improve treatment outcomes for NSCLC.

Dietary methionine restriction impairs anti-tumor immunity through gut microbiota

Methionine restriction-induced sulfur deficiency impairs antitumour immunity partially through gut microbiota

Dietary methionine restriction in cancer development and antitumor immunity

Dietary Methionine Influences Therapy in Mouse Cancer Models and Alters Human Metabolism

Dietary methionine restriction targets one carbon metabolism in humans and produces broad therapeutic responses in cancer

Methionine deficiency facilitates antitumour immunity by altering m6A methylation of immune checkpoint transcripts

The Role of Methionine Restriction in Gastric Cancer: A Summary of Mechanisms and a Discussion on Tumor Heterogeneity

Methionine Restriction Reduces Lung Cancer Progression and Increases Chemotherapy Response

Dietary methionine restriction improves the gut microbiota and reduces intestinal permeability and inflammation in high-fat-fed mice

Unlocking the potential of methionine: a dietary supplement for preventing colitis

Research progress of methionine dependence inhibition of tumor growth

Methionine Metabolism in Health and Cancer: a Nexus of Diet and Precision Medicine

Methionine-driven YTHDF1 expression facilitates bladder cancer progression by attenuating RIG-I-modulated immune responses and enhancing the eIF5B-PD-L1 axis

Dietary Methyl Donor Depletion Suppresses Intestinal Adenoma Development

High methionine intake alters gut microbiota and lipid profile and leads to liver steatosis in mice

Methionine Restriction Increases Exosome Production and Secretion in Breast Cancer Cells

Intermittent dietary methionine deprivation facilitates tumoral ferroptosis and synergizes with checkpoint blockade

Dietary Restriction Increases Protective Gut Bacteria to Rescue Lethal Methotrexate-Induced Intestinal Toxicity.

Effects of Methionine Restriction and Methionine Hydroxy Analogs on Intestinal Inflammation and Physical Barrier Function in Mice

Dietary Methionine Restriction Improves Gut Health and Alters the Plasma Metabolomic Profile in Rats by Modulating the Composition of the Gut Microbiota

Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies